Remove Chronic Pain Remove Clinical Trials Remove Data Remove Law
article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. About RYAH Group, Inc. RYAH Group, Inc.

article thumbnail

Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy

Cannabis Law Report

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Men were more likely than women to treat pain with cannabis.

Data 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

Enters into the Chronic Pain Market with Psychedelics. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. Global Wellness Strategies Inc. ( billion in 2030.

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

article thumbnail

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Cannabis Law Report

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

article thumbnail

Medical cannabis studies offer hope to opioid users

Healer

That is, until a “forward-thinking” primary care physician suggested medical cannabis for his chronic pain, which Gresh, 54, said set him on a new path that has changed his life for the better and helped him stop using virtually all drugs classified as highly addictive. . “I I never thought that would have been possible,” he said. “I